Jiangsu, China

Jianming Zhou

This inventor holds 1 USPTO granted patent. Top assignee: Jiangsu Kanion Pharmaceutical Co., Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianming Zhou. Retrieved from https://idiyas.com/inventor/jianming-zhou-lr5gmelz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jianming Zhou: Innovator in Antibody Development

Introduction

Jianming Zhou is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative antibodies. His work has the potential to impact various therapeutic applications.

Latest Patents

Jianming Zhou holds a patent for an "ANTI-CD38 ANTIBODY AND USE THEREOF." This patent represents a crucial advancement in antibody technology, showcasing his expertise and commitment to innovation in the pharmaceutical industry. He has 1 patent to his name.

Career Highlights

Zhou is currently employed at Jiangsu Kanion Pharmaceutical Co., Ltd., where he continues to push the boundaries of research and development. His role at the company allows him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include Yueheng Han and Zhenzhong Wang. Their collective efforts contribute to the advancement of pharmaceutical research and development.

Conclusion

Jianming Zhou is a dedicated inventor whose work in antibody development is paving the way for future innovations in medicine. His contributions are vital to the ongoing progress in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…